- Home
- » Tags
- » Radioimmunotherapy
Top View
- Trends in Radiopharmaceuticals
- Y-90 Ct84.66), GEMCITABINE and HEPATIC ARTERIAL INFUSION of FUDR for METASTATIC COLORECTAL CARCINOMA to the LIVER
- Y90 Ibritumomab Tiuxetan and I131 Tositumomab
- Practical and Clinical Benefits of Radioimmunotherapy Lead To
- Acr–Acnm–Astro–Snmmi Practice Parameter for the Performance of Therapy with Unsealed Radiopharmaceutical Sources
- Radioimmunotherapy for Metastatic Prostate Cancer
- Radionuclide Metabolic Therapy Clinical Aspects, Dosimetry and Imaging
- 90Y)-Ibritumomab Tiuxetan Radioimmunotherapy (Zevalin®
- What's in a Label? Radioimmunotherapy for Metastatic Prostate Cancer
- Clinical Appropriateness Guidelines
- Radiosurgery Or Hypofractionated Stereotactic Radiotherapy for Brain Metastases from Radioresistant Primaries (Melanoma and Rena
- RIT): Moving Forward Jordan M
- A Primer for Radioimmunotherapy and Radionuclide Therapy
- The Treatment of Low-Grade B-Cell Non-Hodgkin's Lymphomas With
- Radioimmunotherapy of Small Cell Lung Carcinoma with The
- Therapeutic Efficacy of C-Kit-Targeted Radioimmunotherapy Using 90Y-Labeled Anti-C-Kit Antibodies in a Mouse Model of Small Cell Lung Cancer
- 131-Labeled Anti-CEA Monoclonal Antibody NP-4 F(Ab')2
- Yttrium-90-Labeled Anti-CD2O Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma’
- Radioimmunotherapy in Non-Hodgkin Lymphomas
- Intracavitary Radioimmunotherapy of High-Grade Gliomas: Present Status and Future Developments
- Radioimmunotherapy: Recent Advances and Current Opportuni Es
- Current Status of Therapy of Solid Tumors: Brain Tumor Therapy
- Evaluation of Practical Experiences of German Speaking Radiation Oncologists in Combining Radiation Therapy with Checkpoint Blockade Kim M
- ASTRO's Brachytherapy Model Policy
- SUMMARY REPORT December 6, 2002
- ICD-9-CM Expert for Home Health Services, Nursing Facilities, and Hospices Volumes 1, 2 & 3
- Scientific Framework for Small Cell Lung Cancer (SCLC)
- 2004 ICD-9-CM Coding Update
- Radiopharmacy: an Update
- Radioimmunotherapy with Monoclonal Antibodies
- Immunostimulatory Effects of Radiotherapy for Local and Systemic Control of Melanoma: a Review
- Radioimmunotherapy of Human Tumours
- Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice
- Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy
- Brachytherapy: Taking It Forward
- Radioimmunotherapy in the Treatment of Non-Hodgkin Lymphoma
- Radiopharmaceutical Therapy in Cancer: Clinical Advances and Challenges
- Pediatric Hodgkin's Disease
- Iodine-131 Rituximab Radioimmunotherapy: Durable
- Draft Radium-223 Chloride Report, July 3, 2012
- Safety and Efficacy of Robotic Radiosurgery for Visceral
- Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC Beyond Traditional Treatment Approaches
- Update on the Rational Use of Tositumomab and Iodine-131 Tositumomab Radioimmunotherapy for the Treatment of Non-Hodgkin’S Lymphoma
- Nuclear Medicine & Radiation Therapy
- Radioimmunotherapy
- Current Directions in Radiopharmaceutical Research
- Initial Certification Brachytherapy Requirements
- LTR from Lyang, Spectrum Pharmaceuticals, to ACMUI And
- Systemic Radiation Radioimmunotherapy
- Radioimmunotherapy (RIT) Radioimmunotherapy (RIT) Is a Combination of Radiation Therapy and Immunotherapy Used to Treat Non-Hodgkin Lymphoma and Other Types of Cancer
- Radiation Therapy for Brain Metastases
- What Is Radioimmunotherapy?
- Radioimmunotherapy for Breast Cancer Using Indium-Lll/Yttrium-90 Bre-3: Results of a Phase I Clinical Trial Sally J